Unsuspecting consumers are prime targets for fraud, false advertising, and deceptive marketing by unscrupulous companies and fraudsters. Carella Byrne attorneys stand ready to level the playing field. We investigate and litigate a wide variety of claims and have a successful litigation record on behalf of consumers, including:
- James v. Global Tel*Link, No. 13-4989 (D.N.J.): Carella Byrne was co-lead counsel in this action against Global Tel*Link (“GTL)”, the exclusive provider of telephone services for New Jersey state prisons and most New Jersey county jails. This action alleged that GTL took advantage of its position as the exclusive provider of phone services to overcharge prisoners and their families by setting calling rates multiple times in excess of its costs. After years of litigation and successfully defeating two GTL appeals, the case resulted in a claims-made settlement of up to $25 million. As a result of their work, Carella Byrne and their co-counsel were finalists for Public Justice’s 2021 Trial Lawyer of the Year.
- In Re: Vytorin/Zetia Marketing, Sales Practices and Products Liability Litigation, MDL No. 1938 (D.N.J.): Carella Byrne filed the first complaint against Schering-Plough and Merck relating to their marketing of anti-cholesterol drugs Vytorin and Zetia after it was revealed that the companies had been concealing a significant study questioning the effectiveness of the drugs. Carella Byrne, leading hundreds of cases, was appointed Co-Lead Class Counsel and achieved final approval of a $41.5 million settlement on behalf of consumers and third-party payors.
Carella Byrne attorneys are currently litigating the following cases and would be happy to speak to you if you believe you might be impacted by these or any other consumer fraud, false advertising, or deceptive marketing matter. No question is too small. Please contact us today.
- In re Insulin Pricing Litigation, No. 17-699 (D.N.J.): Carella Byrne is Co-Lead Class Counsel representing consumer purchasers of analog insulins. The plaintiffs allege that insulin manufacturers violated multiple consumer protections statutes through an unconscionable pricing scheme to the grave detriment of insulin consumers, all of whom require this life-sustaining drug.